How Prioritizing OpEx Can Raise Sinking Biopharma Valuations

By Kelly Smeltzer

The life sciences industry, composed of pharmaceuticals, biotechnology, and medical devices, advances healthcare to improve the quality of life for people worldwide. However, as investment in the life sciences industry decreases, young companies struggle to keep the lights on. Young companies may overcome these challenges by implementing operational excellence (OpEx) early on in drug development rather than waiting until manufacturing startup. In doing so, they maximize their chances of high valuation and, in turn, robust investment and financial success.